Targeted Protein Degradation Technologies

Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital). He received his PhD in Biomedical Engineering with the highest honor from Shanghai Jiao Tong University, China before completing postdoctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC). Following this he was appointed as Senior Research Associate at the university. Dr. Qin’s research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 120 research papers and reviews. He is an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an editorial board member of more than 10 scientific journals. Dr. Xin Luan received his B.Sc. in Pharmaceutics from China Pharmaceutical University (2011) and was awarded his PhD degree in Pharmacology at Shanghai Jiao Tong University (2016). He subsequently worked for two years as post-doctor at the University of Michigan under the guidance of Professor Duxin Sun. In 2018, he joined Shanghai University of Traditional Chinese Medicine (SHUTCM), and is currently appointed as a professor. He is currently working on anti-tumor pharmacology and delivery systems of natural products. Dr. Luan has published more than 60 research papers and reviews. Dr. Weidong Zhang obtained his BSc and Master degree in Natural Medicinal Chemistry from the Second Military Medical University in 1988 and 1991, respectively. He received his PhD in Natural Medicinal Chemistry from the Shanghai Institute of Pharmaceutical Industry (1998), under the supervision of Professor HuiTing Li. He is currently a professor of the Shanghai University of Traditional Chinese Medicine and Second Military Medical University. His research mainly focuses on Chinese medicine formulas, isolation, structural identification and modification, total synthesis, and structure–activity relationships of bioactive natural products. Dr. Zhang has published more than 500 peer-reviewed research papers and reviews.

• Part 1: Introduction1. Mechanisms of protein degradation2. Overview of targeted protein degradation Part 2: Summary of targeted protein degradation3. Protease-mediate degradation4. PROTAC5. AbTAC6.  Molecular glues7.  Hydrophobic tagging technology8. Lysosome-mediate degradation9. LYTACs10.  Bispecific Apt amer Chimera (BIAC)11.  GlueTAC12. AUTACs13. ATTECs14. AUTOTAC Part 3:  Degradation of Proteins of Interest15. Degraders of signal transduction receptors16. Degraders of membrane-associated proteins17. Degraders of cell cycle- and anti-apoptosis-related proteins18.  Degraders of proteins in epigenetic regulation19. Degraders of proteins involved in transcription nuclear hormone receptors20. Transcription factor degraders Part 4: Clinical applications of targeted protein degradation21. Clinical development of protein degraders